Prosecution Insights
Last updated: October 01, 2026

Examiner: KUCHARCZK, JED A

Tech Center 1600 • Art Units: 1623 1626

This examiner grants 80% of resolved cases

Analysis

Jed A. Kucharczk serves in Tech Center 1600 and Art Unit 1623, where they have overseen 96 resolved cases. The examiner demonstrates an allowance rate pct of 80.2, suggesting a high frequency of grants for applications assigned to this office. This 80.2 allowance rate pct establishes a strong probability of success for practitioners navigating the requirements of Tech Center 1600.

The interview lift pct of 16.7 indicates that conducting an interview provides a measurable benefit to the prosecution process. While the 80.2 allowance rate pct is already high, the 16.7 lift suggests that personal interaction can further clarify claims or resolve examiner concerns. In Art Unit 1623, the 16.7 interview lift pct serves as a useful tool for applicants seeking to expedite their path to a grant.

The median days to allowance for cases under this examiner is 1021. This duration of 1021 days offers a benchmark for applicants to estimate the time required to reach a final resolution. With 96 resolved cases, the data provides a consistent view of the examiner's procedural habits and timelines. Practitioners should factor the 1021 median days to allowance into their long-term planning for intellectual property assets.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

80.2%
Allow Rate
+20.2% vs TC avg
130
Total Applications
+16.7%
Interview Lift
1021
Avg Prosecution Days
Based on 96 resolved cases, 2023–2026

Rejection Statute Breakdown

2.6%
§101 Eligibility
19.8%
§102 Novelty
32.5%
§103 Obviousness
25.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18547800 MELANOCORTIN-4 RECEPTOR AGONIST Non-Final OA LG CHEM, LTD.
18194840 HYPOTONIC MICROBICIDAL FORMULATIONS AND METHODS OF USE Final Rejection The Johns Hopkins University
18548109 SN-38 DERIVATIVE, NANO-PARTICLES CONTAINING SAID DERIVATIVE, MEDICINE, AND METHOD FOR PRODUCING SAID NANO-PARTICLES Final Rejection JAPAN SCIENCE AND TECHNOLOGY AGENCY
19220457 METHODS OF DISPERSING ARIPIPRAZOLE INJECTABLE PREPARATIONS Final Rejection Otsuka Pharmaceutical Co., Ltd.
18556711 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Non-Final OA Nanyang Technological University

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month